Think Research Corporation announce that it has expanded its original contract with a long-term global pharmaceutical client with an additional agreement worth approximately $5.0 million, bringing the total value up to approximately $15.0 million since May 2022. The contract expansion includes new exclusive learning modules and an annual SaaS license added to the Think Learning Management System ("LMS") already delivered throughout 2022 and 2023. The overall agreement encompasses Think's content solutions along with the LMS to provide a broad offering of content, essential data services and software.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.315 CAD | 0.00% | 0.00% | +65.79% |
1st Jan change | Capi. | |
---|---|---|
+65.79% | 18.19M | |
+8.05% | 3,020B | |
+5.58% | 82.93B | |
+3.69% | 76.85B | |
-14.62% | 53.04B | |
+31.16% | 50.15B | |
-24.56% | 46.71B | |
+17.75% | 41.41B | |
+55.21% | 36.1B | |
-10.24% | 24.64B |
- Stock Market
- Equities
- THNK Stock
- News Think Research Corporation
- Think Research Announces $5.0 Million Contract Expansion with a Global Pharmaceutical Company